Kamal Dina, Rady Dina, El Moshy Sara, Radwan Israa Ahmed, Ahmed Nermeen El-Moataz Bellah, Wadan Al-Hassan Soliman, Mehanny Samah S, Eldin Lobna Salah
Oral Biology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt.
Stem cells and Tissue Engineering Research Group, Faculty of Dentistry, Cairo University, Cairo, Egypt.
Sci Rep. 2025 Aug 28;15(1):31722. doi: 10.1038/s41598-025-15924-7.
Mesenchymal stem cells (MSCs)-secretome represent a promising cell-free strategy for bone regeneration, overcoming cell therapies' drawbacks. This study compares the bone repair capabilities of secretomes derived from human dental pulp stem cells (hDPSCs) and human gingival stem cells (hGMSCs) in a rabbit tibial defect model. Secretomes were prepared, and levels of RUNX, osterix, and alkaline phosphatase (ALP) levels were quantified using ELISA. Six-mm defects were created in rabbit tibiae treated with either hDPSCs or hGMSCs secretomes, collagen scaffolds, or left untreated. The mineral apposition rate (MAR) was assessed using fluorescent labeling. Histomorphometric analysis (including bone area percentage, mature/immature bone and bone marrow quantification) and qRT-PCR for osteocalcin were conducted at 3 and 6 weeks. Results showed significantly higher concentrations of RUNX, osterix, and ALP in hDPSCs secretome compared to hGMSCs. Additionally, defects treated with hDPSCs secretome exhibited a higher MAR and greater new bone formation, accelerated maturation (higher mature bone area; p < 0.05), and reduced bone marrow spaces at 3 weeks than those treated with hGMSCs, collagen, or control groups. By 6 weeks, both secretomes achieved comparable bone maturation (83-85% bone area), significantly surpassing controls. Both secretomes upregulated osteocalcin gene expression. These findings show the therapeutic potential of dental MSCs secretomes, and particularly hDPSCs secretomes, as a cell-free, clinically relevant method for improving bone regeneration. This approach addresses limitations associated with traditional bone grafting and possibly presents a new pathway for regenerative therapies in dentistry and orthopedics.
间充质干细胞(MSCs)分泌组代表了一种有前景的无细胞骨再生策略,克服了细胞疗法的缺点。本研究在兔胫骨缺损模型中比较了源自人牙髓干细胞(hDPSCs)和人牙龈间充质干细胞(hGMSCs)的分泌组的骨修复能力。制备了分泌组,并使用酶联免疫吸附测定法(ELISA)对RUNX、osterix和碱性磷酸酶(ALP)水平进行了定量。在兔胫骨上制造6毫米的缺损,分别用hDPSCs或hGMSCs分泌组、胶原支架处理,或不进行处理。使用荧光标记评估矿物质沉积率(MAR)。在3周和6周时进行组织形态计量分析(包括骨面积百分比、成熟/未成熟骨和骨髓定量)以及骨钙素的定量逆转录聚合酶链反应(qRT-PCR)。结果显示,与hGMSCs相比,hDPSCs分泌组中RUNX、osterix和ALP的浓度显著更高。此外,与用hGMSCs、胶原或对照组处理的缺损相比,用hDPSCs分泌组处理的缺损在3周时表现出更高的MAR和更多的新骨形成、加速成熟(更高的成熟骨面积;p < 0.05)以及更小的骨髓腔。到6周时,两种分泌组均实现了相当的骨成熟(骨面积83 - 85%),显著超过对照组。两种分泌组均上调了骨钙素基因表达。这些发现表明,牙源性间充质干细胞分泌组,特别是hDPSCs分泌组,作为一种无细胞、与临床相关的改善骨再生的方法具有治疗潜力。这种方法解决了与传统骨移植相关的局限性,并可能为牙科和骨科的再生治疗提供一条新途径。